ESTRADIOL IS ASSOCIATED WITH DECREASED CARDIOVASCULAR RISK COMPARED TO ETHINYLESTRADIOL WHEN CONTAINED IN COMBINED HORMONAL PREPARATIONS: IMPLICATIONS FOR THE DEVELOPMENT OF NEW ENDOMETRIOSIS THERAPIES